Is AR-V7-positive status a contraindication to enzalutamide therapy?

According to a media release issued by the American Association for Cancer Research (AACR), it may be possible to identify some men with advanced prostate cancer who are highly likely to be resistant to treatment with enzalutamide. … READ MORE …

The potential of metformin in prostate cancer treatment: an update

We have previously commented (more than once) on the perception that metformin may have some value in the management of prostate cancer. A recently reported (albeit small), prospective Swiss study, has added to our knowledge in this regard. … READ MORE …

COMET-1 trial does not show survival benefit … yet

Some in the investment community (and probably many in Exelixis itself) had been hoping that an interim analysis of an ongoing Phase III trial of cabozantinib (Cometriq) in the treatment of late-stage prostate cancer would show a positive outcome and allow the trial to be stopped early. … READ MORE …

AB Science initiates Phase III trial of masitinib in mCRPC, but …

A French company called AB Science has initiated a Phase III clinical trial of masitinib (yet another tyrosine kinase inhibitor) in the treatment of metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

To prednisone or not to prednisone? Is that the question?

The past couple of years have seen a resurgence of academic (and clinical) interest in the value of the corticosteroid prednisone in combination with other drugs in the treatment of men with advanced forms of prostate cancer. … READ MORE …

Results of Phase III trial of custirsen (OGX-011) in mCRPC coming soon

According to a media release issued early this morning by OncoGenex Pharmaceuticals, the Phase III SYNERGY trial of custirsen (originally known as OGX-011) has reached its pre-specified endpoint in terms of the number of events required for final analysis of the trial data. … READ MORE …

Evaluating the risks and benefits of prednisone

Over the past 20 years or so, the oral corticosteroid prednisone has been used regularly in combination with drugs like mitoxantrone, docetaxel, cabazitaxel, ketoconazole, and abiraterone acetate in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

More data from the PREVAIL trial of enzalutamide

Data about the results of the Phase III PREVAIL trial of enzalutamide in men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC) continue to dribble out ahead of the formal presentation … READ MORE …

Abstract of presentation about the PREVAIL trial of enzalutamide in mCRPC

The American Society of Clinical Oncology (ASCO) has released the abstract of the paper by Beer et al. to be presented in full at the upcoming Genitourinary Cancers Symposium in San Francisco late next week … but it doesn’t really tell us anything new. … READ MORE …

Patterns of treatment of European patients with CRPC in 2009-10

The full text of an article by Sternberg et al. (originally published in BMC Urology in 2013) has just been published to the Medscape Oncology web site and addresses patterns of treatment of men with castration-resistant prostate cancer (CRPC) in five European nations before wide availability of abiraterone. … READ MORE …

“Top pick” focuses on advances in treatment of mCRPC

In a new article on the Practice Update web site, Dr. Howard Scher, an oncologist specializing in treatment of advanced prostate cancer at Memorial Sloan-Kettering Cancer Center in New York, writes about his “top pick” regarding new prostate cancer knowledge from 2013. … READ MORE …

Full PREVAIL data to be presented at GU Oncology Symposium

On October 22, Medivation and Astellas Pharma had previously announced a positive result to the PREVAIL trial of enzalutamide vs. placebo in the treatment of men with chemotherapy-naive, metastatic castration-resistant prostate cancer. … READ MORE …

No decrease in mortality rate of newly diagnosed men with metastatic prostate cancer

A newly published paper in the journal Cancer has indicated that, here in the USA, although overall prostate cancer mortality has declined by ~ 40 percent during the past 25 years, there has been no significant decrease in the mortality rate among men who have evident metastatic prostate cancer at time of diagnosis. … READ MORE …

AUA issues urologists with a “pocket guide” on management of CRPC

Some readers may be interested in seeing a new “pocket guide” on the management of non-metastatic and metastatic, castration-resistant prostate cancer (CRPC) that is being made available to urologists here in America by the American Urological Association (AUA). … READ MORE …

Cabozantinib + abiraterone in management of chemo-naive mCRPC

According to a media release issued earlier today by Exelixis, the company has initiated a randomized Phase II clinical trial of cabozantinib + abiraterone + prednisone (CAP) versus abiraterone + prednisone (AP) in chemotherapy-naive men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,074 other followers